Jorge E. Cortes, MD

Articles

Dr. Cortes on Future Directions in MPNs

June 3rd 2020

Jorge E. Cortes, MD, discusses challenges with ruxolitinib in myeloproliferative neoplasms.

Dr. Cortes on the Challenges of Using Ruxolitinib in MPNs

April 24th 2020

Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, discusses the challenges of using ruxolitinib (Jakafi) in patients with myeloproliferative neoplasms (MPNs).

Dr. Cortes on the Safety Profile of Ruxolitinib in MPNs

April 7th 2020

Jorge E. Cortes, MD, discusses the safety profile of ruxolitinib in patients with myeloproliferative neoplasms.

Dr. Cortes on the Utility of Ruxolitinib in MPNs

March 23rd 2020

Jorge E. Cortes, MD, discusses the utility of ruxolitinib in myeloproliferative neoplasms.

Dr. Cortes on the Advantage of BCMA-Targeted Therapy in Multiple Myeloma

March 19th 2020

Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, discusses the advantage of BCMA-targeted therapy in multiple myeloma.

Dr. Cortes on the 192-Week Follow-Up Results of the ENESTop Trial in CML

August 30th 2019

Jorge E. Cortes, MD, deputy chair and professor of medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses The 192-week follow-up results of the ENESTop trial in chronic myeloid leukemia.

Dr. Cortes on Exploring the Use of Quizartinib in AML

March 5th 2019

Jorge E. Cortes, MD, deputy chair of the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the data from the QuANTUM-R trial presented at the 2018 ASH Annual Meeting in relapsed/refractory acute myeloid leukemia (AML).

Dr. Cortes Discusses Quizartinib in AML

September 26th 2018

Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses quizartinib for the treatment of patients with acute myeloid leukemia.

Dr. Cortes Discusses TKI Cessation in CML

March 3rd 2018

Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the success of tyrosine kinase inhibitor (TKI) cessation in patients with chronic myeloid leukemia (CML).

Dr. Cortes Discusses FLT3 Inhibitors in AML

June 22nd 2017

Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses FLT3 Inhibitors in acute myeloid leukemia.

Dr. Cortes on BP-100.01 in Patients With Relapsed/Refractory AML

April 1st 2016

Jorge E. Cortes, MD, deputy department chair, professor of Medicine and Internist, chair, AML Sections, D. B. Lane Cancer Research Distinguished Professor for Leukemia Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the mechanism of action for BP-100.01.

Dr. Cortes Discusses Ponatinib as Initial Therapy for CML

February 5th 2013

Jorge E. Cortes, MD, Department of Leukemia, University of Texas, MD Anderson Cancer Center, discusses the use of ponatinib as initial therapy for patients with chronic myeloid leukemia.

Dr. Cortes on the Phase II Ponatinib PACE Trial

December 12th 2012

Jorge E. Cortes, MD, from the MD Anderson Cancer Center, describes results from a 12 month follow up of the phase II PACE study that examined ponatinib in patients with CML and Ph+ ALL.

Dr. Jorge Cortes Discusses the Ponatinib PACE Trial

June 14th 2012

Dr. Jorge Cortes, from the MD Anderson Cancer Center, Discusses the Ponatinib Ph+All and CML Evaluation (PACE) Trial